MRD detection in B-cell non-hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR

Methods in Molecular Biology

Volumn 971, Issue , 2013, Pages 175-200

  Pott, Christiane ^a   Brüggemann, Monika ^a   Ritgen, Matthias ^a   Van Der Velden, Vincent H J ^b   Van Dongen, Jacques J M ^b   Kneba, Michael ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

B cell Non Hodgkin lymphomas (B NHL); Chronic lymphocytic leukemia (CLL); Follicular lymphoma (FL); Immunoglobulin heavy chain gene (IgH); Mantle cell lymphoma (MCL); Minimal residual disease (MRD); Quantitative range; Real time quantitative PCR (RQ PCR); Sensitivity; T(11; 14) translocation; T(14; 18) translocation

Indexed keywords

ARTICLE; CHROMOSOME 11; CHROMOSOME 18; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENE REARRANGEMENT; IMMUNOGLOBULIN GENE; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SOMATIC MUTATION; ALLELE; B CELL LYMPHOMA; BONE MARROW CELL; DNA SEQUENCE; GENE TRANSLOCATION; GENETICS; HETERODUPLEX ANALYSIS; HUMAN; METHODOLOGY; MONONUCLEAR CELL; PATHOLOGY;

IMMUNOGLOBULIN HEAVY CHAIN; OLIGODEOXYRIBONUCLEOTIDE; PRIMER DNA;

ALLELES; BONE MARROW CELLS; DNA PRIMERS; GENE REARRANGEMENT; HETERODUPLEX ANALYSIS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, B-CELL; NEOPLASM, RESIDUAL; OLIGODEOXYRIBONUCLEOTIDES; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TRANSLOCATION, GENETIC;

MLCS; MLOWN;

EID: 84878656281     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-269-8_10     Document Type: Article

References (35)

1. Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P et al (2007) Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 13:1057-1065
2. Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T et al (2009) Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol 27:6094-6100
3. Hardingham JE, Kotasek D, Sage RE, Gooley LT, Mi JX, Dobrovic A et al (1995) Signi ficance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 13:1073-1079
4. Hirt C, Schuler F, Dolken G (2003) Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab. Semin Cancer Biol 13:223-231
5. Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I et al (2006) Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 12:1270-1276
6. Moos M, Schulz R, Martin S, Benner A, Haas R (1998) The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukemia 12:1971-1976
7. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SMB, Haynes A et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after Alemtuzumab therapy Is associated with prolonged survival. J Clin Oncol 23:2971-2979
8. Pott C, Hoster E, Beldjord K, Macintyre E, Böttcher S, Asna fiV et al (2010) R-CHOP/R-DHAP prior to autologous stem cell transplantation induces higher rates of molecular remission than R-CHOP in younger patients with MCL: results of the MCL younger intergroup trial of the European MCL Network . Blood 116: abstract 528
9. Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Bottcher S, Asna fiV et al (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115:3215-3223
10. Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T et al (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107:2271-2278
11. Provan D, Bartlett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P et al (1996) Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88: 2228-2235
12. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687-2693
13. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A et al (2008) Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004-4013
14. Rambaldi A, Carlotti E, Oldani E, Della SI, Baccarani M, Cortelazzo S et al (2005) Quantitative PCR of bone marrow BCL2/IgH positive cells at diagnosis predicts treatment response and long-term outcome in Follicular non Hodgkin's Lymphoma. Blood 105:3428-3433
15. Andersen NS, Donovan JW, Zuckerman A, Pedersen L, Geisler C, Gribben JG (2002) Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. Exp Hematol 30:703-710
16. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM et al (2009) Preemptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 27:4365-4370
17. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M et al (2002) Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 99:856-862
18. Evans PAS, Pott C, Groenen PJTA, Salles G, Davi F, Berger F et al (2006) Signi ficantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 21:207-214
19. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317
20. Kneba M, Bergholz M, Bolz I, Hulpke M, Batge R, Schauer A et al (1990) Heterogeneity of immunoglobulin gene rearrangements in B-cell lymphomas. Int J Cancer 45:609-613
21. Kneba M, Eick S, Herbst H, Willigeroth S, Pott C, Bolz I et al (1991) Frequency and structure of t(14;18) major breakpoint regions in non-Hodgkin's lymphomas typed according to the Kiel classi fication: analysis by direct DNA sequencing. Cancer Res 51:3243-3250
22. Pott C, Tiemann M, Linke B, Ott MM, von Hofen M, Bolz I et al (1998) Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia 12:1630-1637
23. van der Velden V, van Dongen J (2009) MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. In: Walker JM (ed) Lymphoma: methods and protocols. Humana Press, p. 115-150
24. Olsson K, Gerard CJ, Zehnder J, Jones C, Ramanathan R, Reading C et al (1999) Realtime t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD). Leukemia 13:1833-1842
25. Pott C, Schrader C, Trautmann H, Irmer S, Desgranges C, Ritgen M et al (2003) VH mutational status and VH gene usage de fine molecular heterogeneity in mantle cell lymphoma. Onkologie 26(suppl 5):162
26. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ (2003) Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17:1013-1034
27. van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al (2007) Analysis of minimal residual disease by Ig//TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604-611
28. Payne K, Wright P, Grant JW, Huang Y, Hamoudi R, Bacon CM et al (2011) BIOMED-2 PCR assays for IGK gene rearrangements are essential for B-cell clonality analysis in follicular lymphoma. Br J Haematol 155:84-92
29. Bruggemann M, Droese J, Bolz I, Luth P, Pott C, von Neuhoff N et al (2000) Improved assessment of minimal residual disease in B cell malignancies using fl uorogenic consensus probes for real-time quantitative PCR. Leukemia 14: 1419-1425
30. Donovan JW, Ladetto M, Zou G, Neuberg D, Poor C, Bowers D et al (2000) Immunoglobulin heavy-chain consensus probes for real-time PCR quanti fication of residual disease in acute lymphoblastic leukemia. Blood 95: 2651-2658
31. Akasaka T, Akasaka H, Yonetani N, Ohno H, Yamabe H, Fukuhara S, Okuma M (1998) Re finement of the BCL2/immunoglobulin heavy chain fusion gene in t(14;18)(q32;q21) by polymerase chain reaction amplification for long targets. Genes Chromosomes Cancer 21:17-29
32. Buchonnet G, Lenain P, Ruminy P, Lepretre S, Stamatoullas A, Parmentier F et al (2000) Characterisation of BCL2-JH rearrangements in follicular lymphoma: PCR detection of 3 ¢ BCL2 breakpoints and evidence of a new cluster. Leukemia 14:1563-1569
33. Albinger-Hegyi A, Hochreutener B, Abdou MT, Hegyi I, Dours-Zimmermann MT, Kurrer MO et al (2002) High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocols for their detection. Am J Pathol 160:823-832
34. van Krieken JHJM, Langerak AW, Macintyre EA, Kneba M, Hodges E, Sanz RG et al (2006) Improved reliability of lymphoma diagnostics via PCR-based clonality testing: [mdash] Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 21:201-206
35. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E et al (1998) Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region speci fic TaqMan probes. Leukemia 12:2006-2014